Atorvastatin suppresses NLRP3 inflammasome activation in intracerebral hemorrhage via TLR4- and MyD88-dependent pathways

Abstract

Intracerebral hemorrhage (ICH) is a common neurological condition that causes severe disability and even death. Even though the mechanism is not clear, increasing evidence shows the efficacy of atorvastatin on treating ICH. In this study, we examined the impact of atorvastatin on the NOD-like receptor protein 3 (NLRP3) inflammasome and inflammatory pathways following ICH. Mouse models of ICH were established by collagenase injection in adult C57BL/6 mice. IHC mice received atorvastatin treatment 2 h after hematoma establishment. First, the changes of glial cells and neurons in the brains of ICH patients and mice were detected by immunohistochemistry and western blotting. Second, the molecular mechanisms underlying the microglial activation and neuronal loss were evaluated after the application of atorvastatin. Finally, the behavioral deficits of ICH mice without or with the treatment of atorvastatin were determined by neurological defect scores. The results demonstrated that atorvastatin significantly deactivated glial cells by reducing the expression of glial fibrillary acidic protein (GFAP), Ionized calcium binding adapter molecule 1 (Iba1), tumor necrosis factor (TNF)-α, and interleukin (IL)-6 in ICH model mice. For inflammasomes, atorvastatin also showed its efficacy by decreasing the expression of NLRP3, cleaved caspase-1, and IL-1β in ICH mice. Moreover, atorvastatin markedly inhibited the upregulation of toll-like receptor 4 (TLR4) and myeloid differentiation factor 88 (MyD88), which indicated deactivation of NLRP3 inflammasomes. By inhibiting the activities of inflammasomes in glial cells, neuronal loss was partially prevented by suppressing the apoptosis in the brains of ICH mice, protecting them from neurological defects.

MUC1 attenuates neutrophilic airway inflammation in asthma by reducing NLRP3 inflammasome-mediated pyroptosis through the inhibition of the TLR4/MyD88/NF-κB pathway

“…NLRP3 inflammasome-mediated pyroptosis has been thought to be an important trigger of neutrophil airway inflammation in asthma [ 36 – 38 ]. Previous studies have reported that TLR4 can promote NF-κB activation by interacting with the adapter molecule MyD88, induce NLRP3 inflammasome and caspase-1 activation, and trigger pyroptosis [ 39 – 41 ]. Concurrently, the negative regulatory effect of MUC1 on the TLR4/MyD88/NF-κB pathway has been described in other diseases, such as acute lung injury and acute kidney injury [ 26 , 42 ].…”

Brain-Gut-Microbiota Axis in Amyotrophic Lateral Sclerosis: A Historical Overview and Future Directions

“…Constipation caused by decreased intestinal motility is one of the common clinical manifestations of ALS [ 85 ]. Intestinal motility is mainly regulated by ANS and ENS [ 79 ].…”

“…Activation of NLRP3 inflammasome can regulate caspase-1-dependent pathways and the release of pro-inflammatory cytokines such as IL-1β to respond to cell stress and infection. However, persistent neuroinflammation and brain injury will occur when NLRP3 inflammasome is over-activated [ 85 ], therefore aggravate the symptoms of the disease.…”

Obstructive Sleep Apnea-Associated Intermittent Hypoxia-Induced Immune Responses in Males, Pregnancies, and Offspring

“…Statins, also known as 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors, are a class of cholesterol-lowering medications that also possess cardiovascular protective effects [93]. Atorvastatin, which shows efficacy in attenuating chronic IH-induced myocardial and neural inflammation via suppressing TLR4/MyD88/NF-κB signaling pathways [33,40,94], also suppresses NLRP3 inflammasome activation [95], although this has not been tested in IH models. A recent clinical trial indicates promising protective effects of atorvastatin against cardiovascular risks in OSA patients [96].…”